PIROCARBOTRAT(TM) - A NEW RADIOPHARMACEUTICAL FOR THE TREATMENT OF SOLID TUMORS - COMPARATIVE-STUDIES IN N-NITROSOMETHYLUREA-INDUCED RAT MAMMARY-TUMORS

To evaluate the effectiveness of a single intratumoral dose of Pirocar botrat(TM), a gelatin-protected charcoal suspension labeled with chrom ic [P-32]pyrophosphate, studies of bioelimination, biodistribution and therapeutic action were carried out in rats, and the results obtained were compared with those of other P-32 dispersions. We found that 78. 3% of the treated tumors reduced size after 32 days of treatment. At t hat time, the total eliminated activity was 12.70 +/- 3.90% distribute d in urine (8.30 +/- 1.80%) and feces (4.40 +/- 3.50%). Biodistributio n studies demonstrate that 84.50 +/- 2.60% of the injected activity re mained in the tumor, with no significant concentration in the rest of the organism. We conclude that Pirocarbotrat(TM) can be used as a safe agent for brachytherapy of solid tumors with beta particles. (C) 1997 Elsevier Science Inc.